The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety

Journal of Neurochemistry

Volumn 76, Issue 5, 2001, Pages 1265-1274

  Przedborski, Serge ^a   Jackson Lewis, Vernice ^a   Naini, Ali B ^b   Jakowec, Michael ^c   Petzinger, Giselle ^a   Miller, Reginald ^a   Akram, Muhammad ^a  

^a Columbia University ^*  (United States)

^b Department of Neurology ^*  (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; METHAMPHETAMINE; OXIDOPAMINE; RESERPINE;

ANIMAL MODEL; DOPAMINERGIC NERVE CELL; MOTOR DYSFUNCTION; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PHYLOGENY; PRIORITY JOURNAL; RAT; REVIEW; RIGIDITY; SUBSTANTIA NIGRA; TREMOR;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANIMALS, LABORATORY; LABORATORY PERSONNEL; PARKINSONIAN DISORDERS; SAFETY;

ANIMALIA; PARKINSONIA;

EID: 0035091767     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00183.x     Document Type: Review

References (49)

1. Biochemistry of neurotransmitters in Parkinson's disease
2. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
3. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: Evolution of motor symptoms in the monkey
4. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
5. Chronic parkinsonism secondary to intravenous injection of meperidine analogs
6. Parkinsonism
7. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys
8. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease: Neuropathologic considerations
9. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
10. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice
11. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part I: Systemic administration
12. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium
13. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: Quantitative analysis in seven strains of Mus musculus
14. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors
15. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse
16. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
17. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explain selective toxicity
18. 1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent
19. Relationship of the in vivo metabolism of MPTP to toxicity
20. MPTP toxicity: Implication for research in Parkinson's disease
21. MPTP: The promise of a new neurotoxin
22. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)
23. MPTP: Current concepts and controversies
24. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
25. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
26. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
27. The impact of gender and estrogen on striatal dopaminergic neurotoxicity
28. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
29. Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice
30. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice
31. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion
32. The MPTP-lesioned non-human primate: A model for Parkinson's disease
33. Recommended practices for the safe handling of MPTP
34. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites
35. Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced dopaminergic neurotoxicity
36. The parkinsonian toxin MPTP: Action and mechanism
37. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys
38. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys
39. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP
40. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism
41. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
42. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata
43. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1-metbyl-4-phenylpyridinium
44. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism
45. Selegiline can mediate neuronal rescue rather than neuronal protection
46. MPTP-induced tremor in human and non-human primates
47. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
48. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions
49. Recommended safe practices for using the neurotoxin MPTP in animal experiments